Literature DB >> 23614844

Antihypertensive effects of statins: a meta-analysis of prospective controlled studies.

Alexandros Briasoulis1, Vikram Agarwal, Antonis Valachis, Franz H Messerli.   

Abstract

In experimental studies, statins have been shown to lower blood pressure through increased nitric oxide bioavailability and improved arterial compliance. The clinical significance of this effect remains poorly documented. The authors performed a meta-analysis of the effect of statins on systolic blood pressure (SBP) and diastolic blood pressure (DBP) including prospective randomized, controlled trials of statin therapy. EMBASE and MEDLINE searches for studies in which patients were randomized to treatment with a statin plus standard treatment (or placebo) vs standard treatment (or placebo) were conducted. Studies that provided data on SBP and DBP values before the initiation of the treatment and at the end of the follow-up period were included. A total of 40 studies with 51 comparison groups examining 22,511 controls and 22,602 patients taking statins were examined. Mean SBP in the statin group decreased by 2.62 mm Hg (95% confidence interval [CI], -3.41 to -1.84; P<.001) and DBP by 0.94 mm Hg (95% CI, -1.31 to -0.57; P<.001). In studies including hypertensive patients, the decrease in blood pressures with statins was slightly greater (SBP, -3.07 mm Hg; 95% CI, -4.00 to -2.15 and DBP, 1.04; 95% CI, -1.47 to -0.61). Similarly, statins effectively reduced SBP in diabetic patients. In this large meta-analysis of prospective controlled studies, the authors found a small but statistically significant reduction of SBP in patients taking statins. The decrease in blood pressure may contribute to the pleiotropic effect of statins in reducing cardiovascular risk.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614844      PMCID: PMC8033902          DOI: 10.1111/jch.12081

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  54 in total

1.  Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses.

Authors:  L L Kjaergard; J Villumsen; C Gluud
Journal:  Ann Intern Med       Date:  2001-12-04       Impact factor: 25.391

2.  Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors.

Authors:  Laura Terzoli; Luca Mircoli; Roberta Raco; Alberto U Ferrari
Journal:  J Cardiovasc Pharmacol       Date:  2005-09       Impact factor: 3.105

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins.

Authors:  C Haug; A Schmid-Kotsas; U Zorn; S Schuett; H J Gross; A Gruenert; M G Bachem
Journal:  J Mol Cell Cardiol       Date:  2001-09       Impact factor: 5.000

5.  Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia.

Authors:  Jacek Lewandowski; Maciej Siński; Joanna Bidiuk; Piotr Abramczyk; Anna Dobosiewicz; Agnieszka Ciarka; Zbigniew Gaciong
Journal:  Hypertens Res       Date:  2010-07-29       Impact factor: 3.872

6.  Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.

Authors:  Bryan Williams; Peter S Lacy; J Kennedy Cruickshank; David Collier; Alun D Hughes; Alice Stanton; Simon Thom; Herbert Thurston
Journal:  Circulation       Date:  2008-12-22       Impact factor: 29.690

7.  Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.

Authors:  Toshio Kushiro; Kyoichi Mizuno; Noriaki Nakaya; Yasuo Ohashi; Naoko Tajima; Tamio Teramoto; Shinichiro Uchiyama; Haruo Nakamura
Journal:  Hypertension       Date:  2008-12-22       Impact factor: 10.190

8.  Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension.

Authors:  Kwang Kon Koh; Michael J Quon; Seung Hwan Han; Yonghee Lee; Jeong Beom Park; Soo Jin Kim; Yesl Koh; Eak Kyun Shin
Journal:  Int J Cardiol       Date:  2009-08-03       Impact factor: 4.164

9.  Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.

Authors:  Claudio Borghi; Ada Dormi; Maddalena Veronesi; Zina Sangiorgi; Antonio Gaddi
Journal:  Am Heart J       Date:  2004-08       Impact factor: 4.749

10.  Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling.

Authors:  Charalambos Antoniades; Constantinos Bakogiannis; Paul Leeson; Tomasz J Guzik; Mei-Hua Zhang; Dimitris Tousoulis; Alexios S Antonopoulos; Michael Demosthenous; Kyriakoula Marinou; Ashley Hale; Andreas Paschalis; Costas Psarros; Costas Triantafyllou; Jennifer Bendall; Barbara Casadei; Christodoulos Stefanadis; Keith M Channon
Journal:  Circulation       Date:  2011-07-05       Impact factor: 29.690

View more
  26 in total

1.  Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.

Authors:  Yuriy Sirenko; Ganna Radchenko
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-02-02

2.  Diabetes and age-related demographic differences in risk factor control.

Authors:  Brent M Egan; Jiexiang Li; Tamara E Wolfman; Angelo Sinopoli
Journal:  J Am Soc Hypertens       Date:  2014-05-11

3.  Could Adjunctive Pharmacology Mitigate Cardiovascular Consequences of Obstructive Sleep Apnea?

Authors:  Najib T Ayas; Glen E Foster; Neomi Shah; John Floras; Ismail Laher
Journal:  Am J Respir Crit Care Med       Date:  2019-09-01       Impact factor: 21.405

Review 4.  Prehypertension--prevalence, health risks, and management strategies.

Authors:  Brent M Egan; Sean Stevens-Fabry
Journal:  Nat Rev Cardiol       Date:  2015-02-17       Impact factor: 32.419

Review 5.  Antiplatelet and Lipid-lowering Drugs in Hypertension.

Authors:  Renata Cífková
Journal:  Eur Cardiol       Date:  2014-07

6.  The growing gap in hypertension control between insured and uninsured adults: National Health and Nutrition Examination Survey 1988 to 2010.

Authors:  Brent M Egan; Jiexiang Li; James Small; Paul J Nietert; Angelo Sinopoli
Journal:  Hypertension       Date:  2014-09-02       Impact factor: 10.190

7.  Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals.

Authors:  Brent M Egan; Jiexiang Li; Florence N Hutchison; Keith C Ferdinand
Journal:  Circulation       Date:  2014-10-20       Impact factor: 29.690

8.  Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010.

Authors:  Brent M Egan; Jiexiang Li; Ibrahim F Shatat; J Michael Fuller; Angelo Sinopoli
Journal:  Circulation       Date:  2014-04-14       Impact factor: 29.690

9.  Antihypertensive Treatment Patterns and Blood Pressure Control in Older Adults: Results from the Berlin Aging Study II.

Authors:  Maximilian König; Maik Gollasch; Adrian Rosada; Ilja Demuth; Dominik Spira; Elisabeth Steinhagen-Thiessen
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

10.  A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.

Authors:  Woohyeun Kim; Kiyuk Chang; Eun Joo Cho; Jeong-Cheon Ahn; Cheol Woong Yu; Kyoung-Im Cho; Yong-Jin Kim; Duk-Hyun Kang; Seok-Yeon Kim; Sang-Hak Lee; Ung Kim; Shin-Jae Kim; Young Keun Ahn; Chang Hoon Lee; Jin Ho Shin; Mikyung Kim; Chang Gyu Park
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.